Exploring Markers of Exhausted CD8 T Cells to Predict Response to Immune Checkpoint Inhibitor Therapy for Hepatocellular Carcinoma
Conclusions: CD8 T-cell exhaustion in tumor microenvironment may predict better efficacy of ICI therapy for HCC.Liver Cancer (Source: Liver Cancer)
Source: Liver Cancer - May 12, 2021 Category: Cancer & Oncology Source Type: research
Nerve Fibers in the Tumor Microenvironment as a Novel Biomarker for Oncological Outcome in Patients Undergoing Surgery for Perihilar Cholangiocarcinoma
Conclusion: NFD has been identified as an important novel prognostic biomarker in pCCA patients. NFD alone and in combination with nodal status in particular allows to stratify pCCA patients based on their risk for inferior oncological outcomes after curative-intent surgery.Liver Cancer (Source: Liver Cancer)
Source: Liver Cancer - May 6, 2021 Category: Cancer & Oncology Source Type: research
Comparative Efficacy of Atezolizumab plus Bevacizumab and Other Treatment Options for Patients with Unresectable Hepatocellular Carcinoma: A Network Meta-Analysis
Background: Most phase 3 clinical trials of systemic therapy for first-line unresectable hepatocellular carcinoma (HCC) have failed, with the exception of SHARP, REFLECT, and IMbrave150. We conducted indirect comparisons of therapies evaluated for first-line HCC treatment.Summary: We conducted a systematic review and meta-analysis of treatments for adults with locally advanced or metastatic unresectable HCC and no prior systemic treatment, including atezolizu mab plus bevacizumab, sorafenib, lenvatinib, nivolumab, selective internal radiotherapy (SIRT), transarterial chemoembolization, and placebo or best supportive care...
Source: Liver Cancer - May 6, 2021 Category: Cancer & Oncology Source Type: research
Pembrolizumab as Second-Line Therapy for Advanced Hepatocellular Carcinoma: A Subgroup Analysis of Asian Patients in the Phase 3 KEYNOTE-240 Trial
Conclusion: Pembrolizumab demonstrated antitumor activity and was well tolerated in the Asian subgroup of KEYNOTE-240. A trend toward greater benefit with pembrolizumab in the Asian subgroup was observed compared with the overall cohort, supporting further evaluation of pembrolizumab treatment in this population.Liver Cancer (Source: Liver Cancer)
Source: Liver Cancer - April 27, 2021 Category: Cancer & Oncology Source Type: research
Comparison of Surgical Resection and Systemic Treatment for Hepatocellular Carcinoma with Vascular Invasion: National Cancer Database Analysis
Conclusion: HCC patients with vascular invasion may benefit from surgical resection compared to systemic therapies. Demographic and clinical features of HCC patients and region and type of treating facility were associated with surgical resection versus systemic treatment.Liver Cancer (Source: Liver Cancer)
Source: Liver Cancer - April 23, 2021 Category: Cancer & Oncology Source Type: research
Atezolizumab plus Bevacizumab versus Sorafenib in the Chinese Subpopulation with Unresectable Hepatocellular Carcinoma: Phase 3 Randomized, Open-Label IMbrave150 Study
Conclusion: Clinically meaningful improvements in OS and PFS observed with atezolizumab plus bevacizumab versus sorafenib suggest that atezolizumab plus bevacizumab may become a practice-changing treatment for Chinese patients with unresectable HCC.Liver Cancer (Source: Liver Cancer)
Source: Liver Cancer - April 23, 2021 Category: Cancer & Oncology Source Type: research
Posttreatment after Lenvatinib in Patients with Advanced Hepatocellular Carcinoma
Conclusion: Sorafenib may not be a candidate for use as a posttreatment agent after lenvatinib, according to the results of the present study. Regorafenib has the potential to become an appropriate posttreatment agent after lenvatinib.Liver Cancer (Source: Liver Cancer)
Source: Liver Cancer - April 20, 2021 Category: Cancer & Oncology Source Type: research
APPLE News
Liver Cancer 2021;10:164 –166 (Source: Liver Cancer)
Source: Liver Cancer - April 13, 2021 Category: Cancer & Oncology Source Type: research
Avelumab in Combination with Axitinib as First-Line Treatment in Patients with Advanced Hepatocellular Carcinoma: Results from the Phase 1b VEGF Liver 100 Trial
Conclusion: Treatment with avelumab plus axitinib was associated with a manageable toxicity profile and showed antitumor activity in patients with aHCC.Liver Cancer (Source: Liver Cancer)
Source: Liver Cancer - April 7, 2021 Category: Cancer & Oncology Source Type: research
Real-World Data on Clinical Outcomes of Patients with Liver Cancer: A Prospective Validation of the National Cancer Centre Singapore Consensus Guidelines for the Management of Hepatocellular Carcinoma
Conclusion: The high overall compliance rate and satisfactory clinical outcomes of patients managed according to the NCCS guidelines confirm its validity. This validation using real-world data considers patient and treating clinician preferences, thus providing a realistic analysis of the usefulness of the NCCS guidelines when applied in the clinics.Liver Cancer (Source: Liver Cancer)
Source: Liver Cancer - April 7, 2021 Category: Cancer & Oncology Source Type: research
Downstaging and Resection of Initially Unresectable Hepatocellular Carcinoma with Tyrosine Kinase Inhibitor and Anti-PD-1 Antibody Combinations
Conclusions: Combination of TKI/anti-PD-1 antibodies is a feasible conversion therapy for patients with unresectable HCC to become resectable. This study represents the largest patient cohort on downstaging role of combinational systemic therapy on TKI and PD-1 antibody for HCC.Liver Cancer (Source: Liver Cancer)
Source: Liver Cancer - March 30, 2021 Category: Cancer & Oncology Source Type: research
Disease Burden, Risk Factors, and Recent Trends of Liver Cancer: A Global Country-Level Analysis
Conclusion: We observed an overall increasing trend of liver cancer, especially among male subjects, older individuals, and countries with a higher prevalence of HCV-related liver cancer. More efforts are needed in enhancing lifestyle modifications and accessibility of antiviral treatment for these populations. Future studies should investigate the reasons behind these epidemiological changes.Liver Cancer (Source: Liver Cancer)
Source: Liver Cancer - March 30, 2021 Category: Cancer & Oncology Source Type: research
Time-Varying mHAP-III Is the Most Accurate Predictor of Survival in Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization
Conclusion: An innovative time-varying analysis revealed that mHAP-III was the most accurate model in predicting OS in patients with HCC undergoing TACE. Other clinical pre- and post-TACE variables were also found to be relevant for this prediction.Liver Cancer (Source: Liver Cancer)
Source: Liver Cancer - March 17, 2021 Category: Cancer & Oncology Source Type: research
MRI Features for Predicting Microvascular Invasion of Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis
Conclusions: Seven MRI features including larger tumor size, rim arterial enhancement, arterial peritumoral enhancement, peritumoral hypointensity on HBP, nonsmooth margin, multifocality, and hypointensity on T1WI were significant predictors for MVI of HCC. These MRI features predictive of MVI can be useful in the management of HCC.Liver Cancer (Source: Liver Cancer)
Source: Liver Cancer - March 11, 2021 Category: Cancer & Oncology Source Type: research
Reply to the Letter “Comment on Regarding Manuscript ‘Treatment of Intermediate Stage Hepatocellular Carcinoma in Japan: Position of Curative Therapies’”
Liver Cancer (Source: Liver Cancer)
Source: Liver Cancer - March 11, 2021 Category: Cancer & Oncology Source Type: research
